{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:45:00Z","timestamp":1774925100965,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Healthy Longevity"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lanhl.2024.100639","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T22:34:23Z","timestamp":1727994863000},"page":"100639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of biomarkers in the diagnosis of Alzheimer\u2019s disease in adults with intellectual disability"],"prefix":"10.1016","volume":"5","author":[{"given":"Aoife","family":"McFeely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3721-0197","authenticated-orcid":false,"given":"Sean P","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanhl.2024.100639_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ridd.2010.12.018","article-title":"Prevalence of intellectual disability: a meta-analysis of population-based studies","volume":"32","author":"Maulik","year":"2011","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.lanhl.2024.100639_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3\u00a0solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.100639_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105327","article-title":"Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer\u2019s disease and Down syndrome","author":"Carmona-Iragui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.lanhl.2024.100639_bib6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ridd.2013.02.021","article-title":"Incidence of dementia in older adults with intellectual disabilities","volume":"34","author":"Strydom","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1741-1130.2010.00253.x","article-title":"Dementia in older adults with intellectual disabilities-epidemiology, presentation, and diagnosis","volume":"7","author":"Strydom","year":"2010","journal-title":"J\u00a0Policy Pract Intellect Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1192\/bjp.bp.106.028845","article-title":"Prevalence of dementia in intellectual disability using different diagnostic criteria","volume":"191","author":"Strydom","year":"2007","journal-title":"Br J\u00a0Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/jir.12775","article-title":"Polypharmacy and psychotropic polypharmacy in adults with intellectual disability: a cross-sectional total population study","volume":"64","author":"McMahon","year":"2020","journal-title":"J\u00a0Intellect Disabil Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib10","article-title":"Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study","volume":"6","author":"O\u2019Dwyer","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanhl.2024.100639_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)62026-7","article-title":"The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study","volume":"383","author":"Heslop","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2024.100639_bib12","article-title":"Cognitive reserve and dementia risk management in people with an intellectual disability","volume":"38","author":"Allen","year":"2023","journal-title":"Int J\u00a0Geriatr Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jalz.2018.07.219","article-title":"Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance","volume":"16","author":"Stern","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.100639_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.12688\/hrbopenres.13326.1","article-title":"Sedentary behaviour levels in adults with an intellectual disability: a systematic review and meta-analysis","volume":"4","author":"Lynch","year":"2021","journal-title":"HRB Open Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1467-789X.2006.00296.x","article-title":"The prevalence and determinants of obesity in adults with intellectual disabilities","volume":"8","author":"Melville","year":"2007","journal-title":"Obes Rev"},{"key":"10.1016\/j.lanhl.2024.100639_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jppi.12089","article-title":"Vulnerability to loneliness in people with intellectual disability: an explanatory model","volume":"11","author":"Gilmore","year":"2014","journal-title":"J\u00a0Policy Pract Intellect Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2024.100639_bib18","first-page":"398","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.100639_bib19","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.100639_bib21","first-page":"1598","article-title":"2023\u00a0Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.100639_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.lanhl.2024.100639_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.100639_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.lanhl.2024.100639_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3233\/JAD-160827","article-title":"Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in subjects with Down syndrome","volume":"55","author":"Carmona-Iragui","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.100639_bib27","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","article-title":"Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study","volume":"395","author":"Fortea","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2024.100639_bib28","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1007\/s12035-018-1344-x","article-title":"Fragile X\u00a0and APP: a decade in review, a vision for the future","volume":"56","author":"Westmark","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.lanhl.2024.100639_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050052","article-title":"FMRP mediates mGluR5-dependent translation of amyloid precursor protein","volume":"5","author":"Westmark","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.lanhl.2024.100639_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/156720510791050957","article-title":"Fragile X\u00a0syndrome and Alzheimers disease: another story about APP and beta-amyloid","volume":"7","author":"Malter","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fnmol.2016.00147","article-title":"APP causes hyperexcitability in fragile X\u00a0mice","volume":"9","author":"Westmark","year":"2016","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026549","article-title":"Reversal of fragile X\u00a0phenotypes by manipulation of A\u03b2PP\/A\u03b2 levels in Fmr1KO mice","volume":"6","author":"Westmark","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lanhl.2024.100639_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/srep26052","article-title":"Finding novel distinctions between the sAPP\u03b1-mediated anabolic biochemical pathways in autism spectrum disorder and fragile X\u00a0syndrome plasma and brain tissue","volume":"6","author":"Ray","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanhl.2024.100639_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fncel.2015.00043","article-title":"Fragile X\u00a0mental retardation protein: from autism to neurodegenerative disease","volume":"9","author":"Wang","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13229-023-00574-1","article-title":"Tau reduction attenuates autism-like features in Fmr1 knockout mice","volume":"14","author":"Zhao","year":"2023","journal-title":"Mol Autism"},{"key":"10.1016\/j.lanhl.2024.100639_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neubiorev.2016.06.033","article-title":"Hippocampal dysfunction and cognitive impairment in Fragile-X syndrome","volume":"68","author":"Bostrom","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.lanhl.2024.100639_bib37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/hmg\/ddl004","article-title":"Genomic and functional profiling of duplicated chromosome 15\u00a0cell lines reveal regulatory alterations in UBE3A-associated ubiquitin\u2013proteasome pathway processes","volume":"15","author":"Baron","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035414","article-title":"Abnormal intracellular accumulation and extracellular A\u03b2 deposition in idiopathic and Dup15q11.2-q13\u00a0autism spectrum disorders","volume":"7","author":"Wegiel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lanhl.2024.100639_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/08830738060210062201","article-title":"High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression","volume":"21","author":"Sokol","year":"2006","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1744-9081-8-4","article-title":"A\u00a0novel study on amyloid \u03b2 peptide 40, 42\u00a0and 40\/42 ratio in Saudi autistics","volume":"8","author":"Al-Ayadhi","year":"2012","journal-title":"Behav Brain Funct"},{"key":"10.1016\/j.lanhl.2024.100639_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.9758\/cpn.2020.18.2.270","article-title":"High serum levels of serum 100\u00a0beta protein, neuron-specific enolase, tau, active caspase-3, M30 and M65 in children with autism spectrum disorders","volume":"18","author":"Ayayd\u0131n","year":"2020","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1055\/s-0035-1565273","article-title":"Low serum level \u03b1-synuclein and tau protein in autism spectrum disorder compared to controls","volume":"46","author":"Kadak","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.lanhl.2024.100639_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.107.129551","article-title":"Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model","volume":"323","author":"Vulih-Shultzman","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.lanhl.2024.100639_bib44","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41380-019-0563-5","article-title":"Discovery of autism\/intellectual disability somatic mutations in Alzheimer\u2019s brains: mutated ADNP cytoskeletal impairments and repair as a case study","volume":"26","author":"Ivashko-Pachima","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-020-00904-4","article-title":"Tauopathy in the young autistic brain: novel biomarker and therapeutic target","volume":"10","author":"Grigg","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2015.02.002","article-title":"A\u00a0systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: current state and future research opportunities","volume":"52","author":"Z\u00fcrcher","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.lanhl.2024.100639_bib47","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/ajmg.a.37811","article-title":"Analysis of peripheral amyloid precursor protein in Angelman syndrome","volume":"170","author":"Erickson","year":"2016","journal-title":"Am J\u00a0Med Genet A"},{"key":"10.1016\/j.lanhl.2024.100639_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.844911","article-title":"Metabolic assessment of cerebral palsy with normal clinical MRI using 18F-FDG PET imaging: a preliminary report","volume":"13","author":"Wu","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0887-8994(91)90024-F","article-title":"Regional cerebral glucose metabolism in clinical subtypes of cerebral palsy","volume":"7","author":"Kerrigan","year":"1991","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2013.08.029","article-title":"Hippocampal volume and memory performance in children with perinatal stroke","volume":"50","author":"Gold","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41390-018-0115-8","article-title":"The long-term effect of perinatal asphyxia on hippocampal volumes","volume":"85","author":"Annink","year":"2019","journal-title":"Pediatr Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ridd.2012.07.029","article-title":"Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA)","volume":"34","author":"McCarron","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/CLEP.S242264","article-title":"Incidence rate of advanced chronic kidney disease among privately insured adults with neurodevelopmental disabilities","volume":"12","author":"Whitney","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2024.100639_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76990-7","article-title":"Renal function is associated with blood neurofilament light chain level in older adults","volume":"10","author":"Akamine","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanhl.2024.100639_bib56","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/jir.12100","article-title":"Obesity and associated factors in adults with intellectual disability","volume":"58","author":"Hsieh","year":"2014","journal-title":"J\u00a0Intellect Disabil Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ridd.2011.10.002","article-title":"Inflammation and oxidative stress as biomarkers of premature aging in persons with intellectual disability","volume":"33","author":"Carmeli","year":"2012","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.lanhl.2024.100639_bib59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","article-title":"Immune attack: the role of inflammation in Alzheimer disease","volume":"16","author":"Heppner","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib60","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3\u00a0study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanhl.2024.100639_bib61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3\u00a0trial of flutemetamol labeled with radioactive fluorine 18\u00a0imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib63","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.100639_bib64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","article-title":"Clinical validity of cerebrospinal fluid A\u03b242, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Mattsson","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.lanhl.2024.100639_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lanhl.2024.100639_bib66","first-page":"935","article-title":"Alzheimer\u2019s disease CSF biomarker profiles in idiopathic normal pressure hydrocephalus","volume":"12","author":"Mazzeo","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12987-017-0062-5","article-title":"Cerebrospinal fluid A\u03b242, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.lanhl.2024.100639_bib68","first-page":"1105","article-title":"Elevated CSF LRG and decreased Alzheimer\u2019s disease biomarkers in idiopathic normal pressure hydrocephalus","volume":"10","author":"Vanninen","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib69","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.0000000000000916","article-title":"Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus","volume":"83","author":"Graff-Radford","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.100639_bib70","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/brain\/awx191","article-title":"Glymphatic MRI in idiopathic normal pressure hydrocephalus","volume":"140","author":"Ringstad","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.100639_bib71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X\u00a0syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib73","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fnins.2015.00322","article-title":"From UBE3A to Angelman syndrome: a substrate perspective","volume":"9","author":"Sell","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib74","first-page":"928","article-title":"Autism or atypical autism in maternally but not paternally derived proximal 15q duplication","volume":"60","author":"Cook","year":"1997","journal-title":"Am J\u00a0Hum Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gr.7.4.368","article-title":"The E6\u2013Ap ubiquitin\u2013protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region","volume":"7","author":"Sutcliffe","year":"1997","journal-title":"Genome Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib76","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.lanhl.2024.100639_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","article-title":"Biomarkers for tau pathology","volume":"97","author":"Sch\u00f6ll","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.lanhl.2024.100639_bib78","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F\u00a018\u00a0tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib79","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.lanhl.2024.100639_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54204-z","article-title":"Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanhl.2024.100639_bib81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8\u00a0years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.lanhl.2024.100639_bib83","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanhl.2024.100639_bib84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181\u00a0as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib86","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.lanhl.2024.100639_bib87","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","article-title":"Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies","volume":"3","author":"Montoliu-Gaya","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.lanhl.2024.100639_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib89","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/brain\/awv006","article-title":"Rapidly progressive Alzheimer\u2019s disease features distinct structures of amyloid-\u03b2","volume":"138","author":"Cohen","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.lanhl.2024.100639_bib90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2006.09.014","article-title":"CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment","volume":"251","author":"Stefani","year":"2006","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.lanhl.2024.100639_bib91","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3233\/JAD-190519","article-title":"Highly elevated cerebrospinal fluid total tau level reflects higher likelihood of non-amnestic subtype of Alzheimer\u2019s disease","volume":"70","author":"Pillai","year":"2019","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.100639_bib92","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gps.2353","article-title":"Cerebrospinal fluid total tau as a marker of Alzheimer\u2019s disease intensity","volume":"25","author":"S\u00e4mg\u00e5rd","year":"2010","journal-title":"Int J\u00a0Geriatr Psychiatry"},{"key":"10.1016\/j.lanhl.2024.100639_bib93","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","article-title":"Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury","volume":"67","author":"Ost","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.100639_bib94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","article-title":"Cerebrospinal fluid markers for Alzheimer\u2019s disease evaluated after acute ischemic stroke","volume":"2","author":"Hesse","year":"2000","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.lanhl.2024.100639_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.lanhl.2024.100639_bib96","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/hmg\/ddr603","article-title":"Tau\u2019s role in the developing brain: implications for intellectual disability","volume":"21","author":"Sapir","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib97","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmg.2008.058701","article-title":"Clinical and molecular delineation of the 17q21.31 microdeletion syndrome","volume":"45","author":"Koolen","year":"2008","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib98","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/ng1858","article-title":"Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability","volume":"38","author":"Shaw-Smith","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000091934","article-title":"A\u00a017q21.31 microdeletion encompassing the MAPT gene in a mentally impaired patient","volume":"114","author":"Varela","year":"2006","journal-title":"Cytogenet Genome Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib100","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4103\/1673-5374.386406","article-title":"Amyloid-beta and tau protein beyond Alzheimer\u2019s disease","volume":"19","author":"Abyadeh","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.lanhl.2024.100639_bib101","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ng.3792","article-title":"Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases","volume":"49","author":"Stessman","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.lanhl.2024.100639_bib102","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature21062","article-title":"Prevalence and architecture of de novo mutations in developmental disorders","volume":"542","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.lanhl.2024.100639_bib103","series-title":"Dementia: assessment, management and support for people living with dementia and their carers","year":"2008"},{"key":"10.1016\/j.lanhl.2024.100639_bib104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/alzrt47","article-title":"Role of structural MRI in Alzheimer\u2019s disease","volume":"2","author":"Vemuri","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.100639_bib105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib106","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified\u00a0Alzheimer\u2019s disease","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur J\u00a0Nucl Med Mol Imaging"},{"key":"10.1016\/j.lanhl.2024.100639_bib107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study","volume":"3","author":"Gissl\u00e9n","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanhl.2024.100639_bib108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib109","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A\u00a0multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanhl.2024.100639_bib110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","article-title":"Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study","volume":"20","author":"Carmona-Iragui","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-018-0367-x","article-title":"Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome","volume":"10","author":"Strydom","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanhl.2024.100639_bib113","first-page":"3639","article-title":"Blood biomarkers for Alzheimer\u2019s disease in Down syndrome","volume":"10","author":"Montoliu-Gaya","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.lanhl.2024.100639_bib114","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","article-title":"Detection of brain tau pathology in Down syndrome using plasma biomarkers","volume":"79","author":"Janelidze","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanhl.2024.100639_bib115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mrdd.20144","article-title":"Poverty and people with intellectual disabilities","volume":"13","author":"Emerson","year":"2007","journal-title":"Ment Retard Dev Disabil Res Rev"}],"container-title":["The Lancet Healthy Longevity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682400165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266675682400165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:54:45Z","timestamp":1731621285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266675682400165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S266675682400165X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanhl.2024.100639","relation":{},"ISSN":["2666-7568"],"issn-type":[{"value":"2666-7568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of biomarkers in the diagnosis of Alzheimer\u2019s disease in adults with intellectual disability","name":"articletitle","label":"Article Title"},{"value":"The Lancet Healthy Longevity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanhl.2024.100639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100639"}}